T1780

Parecoxib (SC 69124) is an effective and selective COX-2 inhibitor.

DBCO-PEG4-triethoxysilane is a polyethylene glycol (PEG)-based linker compound that serves as an efficient building block for the synthesis of PROTACs. These PROTACs are small molecules designed to selectively target and degrade specific proteins of interest[1].

DBCO-PEG4-VA-PBD is a cleavable 4-unit PEG ADC linker utilized in antibody-drug conjugate (ADC) synthesis [1].

DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), comprises the ADC linker DBCO-PEG4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which includes metabolites of nemorubicin (MMDX) from liver microsomes and the ADC cytotoxin PNU-159682[1].

DBCO-PEG5-DBCO is a PEG-based linker for PROTACs that joins two essential ligands, crucial for forming PROTAC molecules, enabling selective protein degradation through the ubiquitin-proteasome system within cells.

DBCO-PEG6-amine is a PEG-based linker for PROTACs that connects two essential ligands, facilitating the formation of PROTAC molecules [DBCO-PEG6-amine]. It enables selective protein degradation by utilizing the ubiquitin-proteasome system within cells.

DBCO-PEG8-acid, a PEG-based linker for PROTACs, joins two essential ligands critical for forming PROTAC molecules, enabling selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG8-NHS ester is a PEG-based linker for PROTACs that joins two essential ligands, enabling selective protein degradation through the ubiquitin-proteasome system within cells.

DBCO-PEG9-amine is a PEG-based linker for PROTACs, joining two essential ligands crucial for forming PROTAC molecules, enabling selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG9-DBCO, a PEG-based linker for PROTACs, connects two essential ligands to form PROTAC molecules, enabling selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Parecoxib sodium is a prodrug of Valdecoxib and a selective, orally active COX-2 inhibitor that suppresses prostaglandin (PG) synthesis and alleviates pain and inflammation. Parecoxib sodium also acts as a cannabinoid 1 (CB1) receptor agonist (EC50=2.4 µM).